Desferrioxamine-chelatable iron, a component of serum non–transferrin-bound iron, used for assessing chelation therapy by William Breuer, Marieke J. J.

Slides:



Advertisements
Similar presentations
Hemoglobin A 2 Practical Hematology Lab - LAB 6 -.
Advertisements

Methods to Detect Red Cell Membrane Disorders
Methods to Detect Red Cell Membrane Disorders
An anti-CD19 antibody inhibits the interaction between P-glycoprotein (P-gp) and CD19, causes P-gp to translocate out of lipid rafts, and chemosensitizes.
One-Stage Quantitative
Kinetics analysis of β-fructofuranosidase enzyme
In Vitro Discriminative Antipseudomonal Properties Resulting from Acyl Substitution of N-Terminal Sequence of Dermaseptin S4 Derivatives  Keren Marynka,
Volume 63, Issue 2, Pages (February 2003)
Fluorescence Polarization Immunoassay FPIA
Volume 21, Issue 1, Pages (January 2014)
Methods to Detect Red Cell Membrane Disorders
Determination of Protein Concentration of a Solution
An anti-CD20–IL-2 immunocytokine is highly efficacious in a SCID mouse model of established human B lymphoma by Stephen D. Gillies, Yan Lan, Steven Williams,
IFNα-stimulated neutrophils and monocytes release a soluble form of TNF-related apoptosis-inducing ligand (TRAIL/Apo-2 ligand) displaying apoptotic activity.
Volume 21, Issue 1, Pages (January 2014)
Tissue-Specific Expression of Functional Platelet Factor XI Is Independent of Plasma Factor XI Expression by Chang-jun Hu, Frank A. Baglia, David C.B.
Variations in glycosylation of von Willebrand factor with O-linked sialylated T antigen are associated with its plasma levels by Carina J. M. van Schooten,
Kinetics and mechanics of clot contraction are governed by the molecular and cellular composition of the blood by Valerie Tutwiler, Rustem I. Litvinov,
PRT , a novel Syk inhibitor, prevents heparin-induced thrombocytopenia and thrombosis in a transgenic mouse model by Michael P. Reilly, Uma Sinha,
Single-Color Digital PCR Provides High-Performance Detection of Cancer Mutations from Circulating DNA  Christina Wood-Bouwens, Billy T. Lau, Christine.
by Martha B. Johnson, and Caroline A. Enns
Recombinant factor VIIa restores aggregation of αIIbβ3-deficient platelets via tissue factor–independent fibrin generation by Ton Lisman, Jelle Adelmeijer,
Intracellular labile iron pools as direct targets of iron chelators: a fluorescence study of chelator action in living cells by Hava Glickstein, Rinat.
Plasminogen-mediated matrix invasion and degradation by macrophages is dependent on surface expression of annexin II by Domenick J. Falcone, Wolfgang Borth,
Activation of the Erythropoietin Receptor Is Not Required for Internalization of Bound Erythropoietin by Diana L. Beckman, Lilie L. Lin, Mary E. Quinones,
Distinct dose-dependent effects of plasmin and TPA on coagulation and hemorrhage by Daphne Stewart, Mansze Kong, Valery Novokhatny, Gary Jesmok, and Victor.
by Zhengyan Wang, Tina M. Leisner, and Leslie V. Parise
by Kirsteen H. Maclean, John L. Cleveland, and John B. Porter
Anan Abu Ubeid, Longmei Zhao, Ying Wang, Basil M. Hantash 
Elevated prothrombin results in clots with an altered fiber structure: a possible mechanism of the increased thrombotic risk by Alisa S. Wolberg, Dougald.
Quantitative Proteins Estimation by Lowry method
The interplay between tissue plasminogen activator domains and fibrin structures in the regulation of fibrinolysis: kinetic and microscopic studies by.
Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy by Mark P. Chao, Chad Tang, Russell K. Pachynski,
Hemolysis is a primary ATP-release mechanism in human erythrocytes
Increased survival is a selective feature of human circulating antigen-induced plasma cells synthesizing high-affinity antibodies by Inés González-García,
by Cornelis van 't Veer, Neal J. Golden, and Kenneth G. Mann
by Matthew F. Whelihan, Vicentios Zachary, Thomas Orfeo, and Kenneth G
Kinetic Studies on Enzyme-Catalyzed Reactions: Oxidation of Glucose, Decomposition of Hydrogen Peroxide and Their Combination  Zhimin Tao, Ryan A. Raffel,
by Xingwei Sui, Sanford B. Krantz, and Zhizhuang Zhao
Antibodies associated with heparin-induced thrombocytopenia (HIT) inhibit activated protein C generation: new insights into the prothrombotic nature of.
Apoptotic Vascular Endothelial Cells Become Procoagulant
by Jun Yuan, David B. Lovejoy, and Des R. Richardson
C1qTNF–related protein-1 (CTRP-1): a vascular wall protein that inhibits collagen-induced platelet aggregation by blocking VWF binding to collagen by Gerald.
Platelet-Derived Interleukin-1 Induces Cytokine Production, but not Proliferation of Human Vascular Smooth Muscle Cells by Harald Loppnow, Rosita Bil,
by Eleanor J. Molloy, Amanda J. O'Neill, Julie J
Volume 113, Issue 12, Pages (December 2017)
Volume 86, Issue 1, Pages (January 2004)
Evaluation of Pre-Analytical Variables in the Quantification of Dengue Virus by Real- Time Polymerase Chain Reaction  Azlinda Anwar, Guoqiang Wan, Kaw-Bing.
Practical Hematology Lab Osmotic Fragility Test
Volume 88, Issue 4, Pages (April 2005)
Activation of Phosphoinositide 3-Kinase γ by Ras
Expansion and Homing of Adoptively Transferred Human Natural Killer Cells in Immunodeficient Mice Varies with Product Preparation and In Vivo Cytokine.
Nachiket Shembekar, Hongxing Hu, David Eustace, Christoph A. Merten 
Volume 67, Issue 3, Pages (March 2005)
Volume 97, Issue 1, Pages (July 2009)
Molecular Therapy - Methods & Clinical Development
Sofia Yu. Khaitlina, Hanna Strzelecka-Gołaszewska  Biophysical Journal 
Identification of Small Molecule Inhibitors that Distinguish between Non-Transferrin Bound Iron Uptake and Transferrin-Mediated Iron Transport  Jing Xu.
In Vitro Keratinocyte Dissociation Assay for Evaluation of the Pathogenicity of Anti- Desmoglein 3 IgG Autoantibodies in Pemphigus Vulgaris  Ken Ishii,
Domain Interactions in E
Volume 96, Issue 3, Pages (February 1999)
Anti–protamine-heparin antibodies: incidence, clinical relevance, and pathogenesis by Tamam Bakchoul, Heike Zöllner, Jean Amiral, Simon Panzer, Sixten.
Volume 23, Issue 2, Pages (July 2006)
Rinat Nahum-Levy, Dafna Lipinski, Sara Shavit, Morris Benveniste 
Practical Hematology Lab Osmotic Fragility Test
Volume 9, Issue 5, Pages (May 2001)
Practical Hematology Lab Osmotic Fragility Test
by Sarah M. Nordstrom, Brian A. Holliday, Brandon C. Sos, James W
Iron concentration is higher in the serum of TPs than that of HVs
Volume 13, Issue 4, Pages (April 2005)
Presentation transcript:

Desferrioxamine-chelatable iron, a component of serum non–transferrin-bound iron, used for assessing chelation therapy by William Breuer, Marieke J. J. Ermers, Pensri Pootrakul, Ayala Abramov, Chaim Hershko, and Z. Ioav Cabantchik Blood Volume 97(3):792-798 February 1, 2001 ©2001 by American Society of Hematology

Scheme of the DCI assay.The scheme depicts the steps of the assay for both normal (left) and NTBI-containing sera (right). Scheme of the DCI assay.The scheme depicts the steps of the assay for both normal (left) and NTBI-containing sera (right). The iron is depicted as a filled circle and the Tf molecules denoted by ‘T’. Step 1: Serum samples are mixed with reagent A (HBS containing 2.5 μM fluorescein-DFO [Fl-DFO, *]) or reagent B (same as reagent A, but containing 100 μM DFO, **) in the wells. In reagent A the accessible Fe binds to the Fl-DFO and quenches its fluorescence, whereas in reagent B the Fe binds to the excess nonfluorescent DFO rather than to Fl-DFO. Step 2: Fluorescence is determined after a 2-hour incubation. In normal serum, the ratio of fluorescence of samples treated with reagent A and B is near 1, whereas in Fe-containing serum, the fluorescence in reagent A is lower than in B, giving a ratio less than 1. The ratio of the fluorescence readings (A/B) is inversely proportional to the concentration of DCI in the original sample. William Breuer et al. Blood 2001;97:792-798 ©2001 by American Society of Hematology

Calibration of Fe concentration versus fluorescence Calibration of Fe concentration versus fluorescence.A series of concentrations of Fe, ranging from 0 to 200 μM (described in “Patients, materials, and methods”), was prepared by serial dilution of Fe:NTA in HBS buffer (input sample). Calibration of Fe concentration versus fluorescence.A series of concentrations of Fe, ranging from 0 to 200 μM (described in “Patients, materials, and methods”), was prepared by serial dilution of Fe:NTA in HBS buffer (input sample). From each dilution 20 μL was transferred to 96-well plates followed by 100 μL 2.5 μM Fl-DFO in HBS. Replicate wells were treated with the same reagents containing in addition 100 μM DFO, to give the “maximal” fluorescence for each sample. The fluorescence ratio (expressed as “% of maximal value” obtained in the presence of excess DFO) was calculated for each sample (see “Patients, materials, and methods”) and plotted semilogarithmically against the concentration of Fe in the original 20-μL input sample (A). The linear region of the calibration curve (0-6.25 μM Fe) is shown in panel B. The values are averages ± SD of 6 separate calibration curves. The boxed area labeled “48 control sera” represents the range of values obtained for serum samples of 48 individuals without Fe overload. William Breuer et al. Blood 2001;97:792-798 ©2001 by American Society of Hematology

DCI in patients during L1 therapy DCI in patients during L1 therapy.Blood samples from 11 patients with thalassemia major were taken immediately before (0 minute) and at intervals of 30 minutes after administration of L1 (75 mg/kg) per os. DCI in patients during L1 therapy.Blood samples from 11 patients with thalassemia major were taken immediately before (0 minute) and at intervals of 30 minutes after administration of L1 (75 mg/kg) per os. Two groups of patients were tested, 8 in Israel (open symbols) and 3 in Thailand (filled symbols). Serum was isolated from the samples after overnight storage at 4°C, and stored frozen. All samples were assayed for DCI in duplicate as described in “Patients, materials, and methods.” Dashed line indicates 0 value. William Breuer et al. Blood 2001;97:792-798 ©2001 by American Society of Hematology

Spectrophotometric determination of Fe transfer from L1 to DFO Spectrophotometric determination of Fe transfer from L1 to DFO.A complex of L1-Fe was formed by mixing Fe and NTA (5 mM FAS:35 mM NTA) with L1 to give final concentrations of 100 μM L1 and 10 μM Fe, followed by incubation for 1 hour at room temperature. Spectrophotometric determination of Fe transfer from L1 to DFO.A complex of L1-Fe was formed by mixing Fe and NTA (5 mM FAS:35 mM NTA) with L1 to give final concentrations of 100 μM L1 and 10 μM Fe, followed by incubation for 1 hour at room temperature. A spectrum (range, 350-550 nm) of the L1-Fe complex was obtained (“L1-Fe complex”), followed by addition of 50 μM DFO to the cuvette, incubation for 10 minutes, and determination of a second spectrum (“L1-Fe complex + DFO”). The “DFO-Fe complex” was generated by mixing Fe and NTA (5 mM FAS:35 mM NTA) with DFO, to give final concentrations of 50 μM DFO and 10 μM Fe and incubating for 1 hour. The absorbance dip at 470 nm is due to instrument noise. William Breuer et al. Blood 2001;97:792-798 ©2001 by American Society of Hematology

Time dependence of Fe transfer from L1 to Fl-DFO Time dependence of Fe transfer from L1 to Fl-DFO.Preformed L1-Fe complexes containing 2 μM Fe and increasing concentrations of L1 (0-16 μM) were prepared from Fe:NTA and L1 as described in Figure 4. Time dependence of Fe transfer from L1 to Fl-DFO.Preformed L1-Fe complexes containing 2 μM Fe and increasing concentrations of L1 (0-16 μM) were prepared from Fe:NTA and L1 as described in Figure 4. At 0 minute, 20 μL of each solution was mixed with 100 μL 2.5 μM Fl-DFO in HBS, and the fluorescence was monitored with time. The final concentrations of both Fe and Fl-DFO were 2 μM in each system, whereas the concentration of L1 (μM) varied: ▪, 0; ●, 2; ▴, 4; ▾, 8; ♦, 16. William Breuer et al. Blood 2001;97:792-798 ©2001 by American Society of Hematology

Time dependence of Fe transfer from L1 to apo-Tf Time dependence of Fe transfer from L1 to apo-Tf.Two solutions were prepared in HBS, one containing 12 μM Fe as Fe:NTA, and the other preformed L1-Fe complexes containing 100 μM L1 and 12 μM Fe. From each solution 20 μL was mixed with an equal volume of eit... Time dependence of Fe transfer from L1 to apo-Tf.Two solutions were prepared in HBS, one containing 12 μM Fe as Fe:NTA, and the other preformed L1-Fe complexes containing 100 μM L1 and 12 μM Fe. From each solution 20 μL was mixed with an equal volume of either HBS or HBS containing 25 μM apo-Tf, and incubated for 15 minutes at room temperature. To each mixture was added 100 μL 2.5 μM Fl-DFO in HBS and the fluorescence was monitored with time: ▪, Fe + apo-Tf; ●, L1-Fe + apo-Tf; ▾, L1-Fe; ▴, Fe alone. The final concentrations of L1, Fe, apo-Tf, and Fl-DFO in the reaction mixture were 14.3, 1.7, 3.6, and 1.8 μM, respectively. William Breuer et al. Blood 2001;97:792-798 ©2001 by American Society of Hematology

Apo-Tf extracts Fe from L1-Fe complexes formed in vivo Apo-Tf extracts Fe from L1-Fe complexes formed in vivo.Serum samples taken from 2 patients (NN and AH) immediately after L1 administration (▪) (Figure 3) were mixed with apo-Tf (●) or DFO (▴) (final concentrations 0.5 mg/mL and 50 μM, respectively) for 15 m... Apo-Tf extracts Fe from L1-Fe complexes formed in vivo.Serum samples taken from 2 patients (NN and AH) immediately after L1 administration (▪) (Figure 3) were mixed with apo-Tf (●) or DFO (▴) (final concentrations 0.5 mg/mL and 50 μM, respectively) for 15 minutes at room temperature. The samples were then assayed for DCI as described. Dashed line indicates 0 value. William Breuer et al. Blood 2001;97:792-798 ©2001 by American Society of Hematology

DCI in patients during L1-DFO combination therapy DCI in patients during L1-DFO combination therapy.Blood samples of 8 patients with thalassemia major were taken immediately before (0 minutes) and at intervals of 30 minutes after oral administration of L1, followed by 30- to 60-minute intravenous infusion ... DCI in patients during L1-DFO combination therapy.Blood samples of 8 patients with thalassemia major were taken immediately before (0 minutes) and at intervals of 30 minutes after oral administration of L1, followed by 30- to 60-minute intravenous infusion of DFO (shown by arrows). Serum was obtained from the blood samples after overnight storage at 4°C and subsequently stored frozen. All samples were assayed for DCI in duplicate as described in “Patients, materials, and methods.” Dashed line indicates 0 value. William Breuer et al. Blood 2001;97:792-798 ©2001 by American Society of Hematology